Les lauréats de l'appel à projets Grants 2018

Cette année, une enveloppe de 22,6 millions d’euros était prévue pour la sélection des projets « Grants scientifiques 2018 ».

Au final, ce sont 24,8 millions d’euros qui ont été octroyés pour le soutien de 74 projets de recherche. Ce superbe résultat constitue un véritable record obtenu grâce à la seule générosité de nos donateurs ! Qu’ils en soient très chaleureusement remerciés !

Nous vous présentons ci-dessous la liste des lauréats 2018.

• En recherche fondamentale, 30 projets ont été sélectionnés et ils bénéficieront d’une enveloppe budgétaire globale de 13 795 611 €.
• En recherche translationnelle et clinique, 38 projets ont été sélectionnés et ils bénéficieront d’une enveloppe budgétaire globale de 9 407 735 €.
• L’appel ciblé « Amiante » a abouti à la sélection de 6 projets qui bénéficieront d’une enveloppe budgétaire globale de 1 589 000 €.

Selection Grants Fundamental: 30 projets - 13 795 611€ 

• Agostinis Patrizia, KU Leuven
  • Harnessing autophagy in the tumor microenvironment for the improvement of radiation mediated anti-tumor immunity
• Amant Frédéric, KU Leuven
  • Evaluation of chemotherapy-associated fetal damage in cancer in pregnancy
• Beck Benjamin, ULB
  • Characterisation of the metaplasia-to-adenocarcinoma transition in the oesophagus
• Bergers Gabriele, KU Leuven
  • UNRAVELLING AND TARGETING MICROGLIA-DRIVEN GLIOMA INVASION
• Constantinescu Stefan, De Duve Institute
  • Mechanisms of Progression of Myeloproliferative Neoplasms to Secondary Acute Leukemia: Key Roles of Persistent STAT5 Activation and p53 mutants
• Cools Jan, KU Leuven
  • Oncogenic cooperation at STAT5 transcriptional complexes
• Coulie Pierre, de Duve Institute
  • Early T lymphocyte responses to human breast carcinomas
• Decottignies Anabelle, UCL & Messens Joris, VUB
  • The ALTernative mechanism of telomere maintenance: a potential therapeutic target for cancer treatment?
• Dequiedt Franck, ULIège
  • A new perspective on Ewing's Sarcoma
• Gerhardt Holger, KU Leuven
  • Exploring progressive endothelial heterogeneity as mechanism of therapy resistance in glioma
• Goriely Stanislas, ULB
  • Understanding the critical role of mRNA stability control in oncogenesis and its impact on anti-tumoral immune responses
• Jacquemin Patrick, UCL
  • Mechanisms of resistance to oncogenic mutations of Kras in pancreatic acinar cells
• Lambrechts Diether, KU Leuven
  • Dissecting complex tumor microenvironment dynamics during immune checkpoint inhibition using single-cell profiling
• Lemaigre Frédéric, De Duve institute
  • Mechanisms of tumor progression in cholangiocarcinoma
• Leucci Eleonora, KU Leuven
  • Exploiting lncRNAs to drug the undruggable in BRAF wild-type melanoma
• Marine Jean-Christophe, KU Leuven
  • Preventing therapy-induced stemness as a salvage strategy to precision oncology
• Mestdagh Pieter, UGent
  • The role of the neuroblastoma-specific long non-coding RNA NESPR in neuroblastoma tumor development.
• Moser Muriel, ULB
  • Murine models of checkpoint blockade
• Noel Agnès, ULiège
  • Implication of lymphatic heterogeneity and plasticity in metastatic dissemination
• Sablina Anna, KU Leuven & Steyaert Jan, VUB
  • Nanobody-based approach to inhibit RAS activity by modulating its interactome
• Schymkowitz Joost, KU Leuven
  • Protein Aggregation as a treatment to Cancer
• Sonveaux Pierre, UCL
  • Lactate dehydrogenase B (LDHB) inhibition for anticancer treatment
• Speleman Frank, UGent
  • SOX11 regulatory control of the epigenetic neuroblastoma super-enhancer landscape
• Swinnen Johan, KU Leuven
  • Fatty acid metabolism as a novel adaptive response to high intratumoral pressure/temperature and promising target for the treatment of solid tumors
• Thielemans Kris, VUB
  • Prioritization of neoantigens by the combination of  in silico search and mass spectrometry
• Van den Eynde Benoit, Institut de Duve
  • Discovery of New Onco-Immunology Targets
• van der Bruggen Pierre, Institut de Duve
  • How to promote sustained antitumor CD8 T cell responses? A focus on transcription factors
• Vandesompele Jo, UGent
  • Breaking the circle - exploiting circRNAs in cancer
• Van Loo Geert, U Gent
  • OTULIN in hepatocyte cell death and hepatocellular carcinoma
• Van Vlierberghe Pieter, UGent
  • The role of BRWD2/PHIP as a novel epigenetic tumor suppressor in T-cell acute lymphoblastic leukemia and lymphoma

Translationnal & Clinical Grants: 38 projets - 9 407 735 € 

• Awada Ahmad, ULB- Bordet
  • The BrainStorm cerebrospinal fluid translational study in patients with CNS metastases from solid tumors : A substudy of the « BrainStorm » Brain Metastases Clinical Research Platform
• Baron Frédéric, U Liège
  • Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel versus Flu-Mel-ATG reduced-intensity conditioning: a phase III randomized study from the Belgian Hematology Society (BHS)​
• Blanpain Cédric, ULB
  • Clinical relevance of a novel and universal marker of solid tumors
• Bours Vincent, U Liège
  • Analysis of circulating biomarkers associated with patient's immune status to predict response to chemotherapy in early breast cancer
• Caveliers Vicky, VUB
  • Visualizing immunosuppressive PD-L1 expression in tumors using anti-PD-L1 sdAb PET-CT scan: a new strategy for accurate patient selection in targeted immune-activating cancer therapy
• Daisne Jean-François, CSME Namur & Duprez Frédéric, U Gent, & Lawson Georges, Clin. Univ. St-Luc & Van Gestel Dirk, Institut Bordet
  • A prospective randomized phase 2 study of dose and volume de-escalation in prophylactic nodal irradiation of contralateral neck by sentinel lymph nodes mapping in unilaterally node positive head and neck squamous cell carcinomas​
• Delforge Michel, KU Leuven
  • Unravelling the mechanisms of drug resistance to proteasome inhibitors to optimize treatment in patients with multiple myeloma​
• De Meerleer Gert, UZ Leuven
  • Metastasis-directed therapy in castration-refractory prostate cancer: MEDCARE​
• Demeestere Isabelle, ULB
  • Breast cancer in young BRCA mutated patients: fertility preservation strategy and gonadotoxicity of the new therapeutic options.​
• De Moerloose Barbara, UZ Gent
  • Therapeutic targeting of newly identified Juvenile Myelomonocytic Leukemia (JMML)-specific long non-coding RNAs.
• Demoulin Jean-Baptiste, De Duve Institute
  • New targets for the diagnosis and treatment of infantile myofibromatosis​
• De Neve Wilfried, U Gent
  • Cardiac and lung toxicity reduction using prolonged deep-inspiration breath hold combined with prone crawl position for patients requiring radiotherapy of breast/thoracic wall and regional lymphnodes​​
• Desmedt Christine, KU Leuven
  • Association between different measures of global and local adiposity with clinico-pathological features, circulating markers, lipidomic profiles and outcome in postmenopausal breast cancer patients treated in the IBCSG 35-07 (SOLE) / BIG 1-07 trial
• Detry Olivier, U Liège
  • Extension of liver transplantation opportunity to patients suffering from Milan-out, Up-to-7-in, hepatocellular carcinoma: a prospective Belgian study of  the value of negative 18FDG PET/CT​
• Dierickx Daan, KU Leuven
  • The identification of actionable genetic events driving disease progression and heterogeneity in peripheral T cell lymphoma, not otherwise specified​
• Flamen Patrick, ULB- Bordet
  • Molecular biomarkers in metastatic castrate resistant prostate cancer:  PSMA-receptor expression, metabolic activity, and circulating cell-free DNA.
• Haustermans Karin, UZ Leuven
  • Extreme hypofractionated radiotherapy with a simultaneously integrated boost to the intraprostatic tumor to improve treatment outcome in prostate cancer
• Hendrix An, U Gent
  • Evaluation of treatment responsiveness based on extracellular vesicle protein signatures in sarcoma patients and their PDX.​
• Ignatiadis Michail, ULB- Bordet
  • Mapping of the immune landscape after CDK4/6 inhibitors in ER+/HER2- breast cancer​
• Kerre Tessa, U Gent
  • An in-depth investigation of the causes of treatment failure in AML
• Kridelka Frédéric, U Liège
  • Lymph node profiling in advanced cervical cancer
• Lion Eva, UZ Antwerpen
  • First-in-human autologous dendritic cell immunotherapy engineered to transpresent interleukin-15 and suppress programmed death-1 signaling
• Machiels Jean-Pascal, UCL
  • Restoring anti-tumour immunity by shutting down COX-2-mediated constitutive IDO1 expression with celecoxib​
• Neyns Bart, UZ Brussel
  • Expanding the potential applications of BRAF and MEK inhibition for the treatment of patients with advanced BRAF V600 wild-type melanoma​
• Sotiriou Christos, ULB - Bordet
  • Integrative multi-omic analysis: towards treatment de-escalation for early-stage HER2-positive breast cancer​
• Speleman Frank, U Gent
  • Exploration of replicative stress and transcriptional addiction as novel therapeutic vulnerabilities in neuroblastoma​
• Sterpin Edmond, KU Leuven
  • AcCEPT: adaptive cost effective proton therapy​
• Tejpar Sabine, KU Leuven
  • Profiling of the colorectal tumor (CRC) immune microenvironment (TME) to identify novel therapeutic opportunities and biomarkers​
• Thielemans Kris, VUB
  • TriMixDC-NEO
• Uyttebroeck Anne, UZ Leuven
  • Improving the quality of survival after childhood cancer by monitoring late effects
• Vanden Berghe Tom, U Gent
  • Nanoparticle-based ferroptosis-induction to treat neuro- and glioblastoma​
• Van Laethem Jean-Luc, ULB – Erasme & Rooman Ilse, VUB
  • GPS (Gene alteration Positioning System) in pancreatic cancer and its microenvironment, a pragmatic molecular classifier to be used in a window neoadjuvant platform​
• Van Vlierberghe Pieter, U Gent
  • Towards a broader use of a less toxic L-asparaginase variant for the treatment of human cancer​
• Vergote Ignace, KU Leuven
  • Comprehensive genomic and transcriptomic analysis of high grade serous ovarian cancer using single-cell RNA-sequencing​
• Vermeesch Joris, UZ Leuven
  • Genomic and epigenomic profiling of circulating tumor DNA for non-invasive breast cancer detection​
• Verslype Chris, KU Leuven
  • Methylome analysis in circulating tumor DNA to predict baseline or acquired sorafenib resistance in hepatocellular carcinoma patients​
• Wildiers Hans, UZ Leuven
  • A METABOLOMICS SIGNATURE ON LIQUID BIOPSY AS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN EARLY BREAST CANCER​

Grants Asbestos: 6 projets - 1 589 000 € 

• Gevaert Kris, U Gent
  • A novel proteomics-based approach to find more accurate biomarkers for mesothelioma
• Roger Pierre, ULB
  • Preclinical evaluation of CDK4 inhibitory drugs and predictive sensitivity biomarkers in malignant pleural mesotheliomas. 
• Bollen Mathieu, KU Leuven
  • Targeting a timer-integrator of cell cycle checkpoint signaling for mesothelioma therapy
• Cataldo Didier ULiège
  • Mechanisms of chemotherapy resistance in mesothelioma
• Lison Dominique UCL
  • Fibres, macrophages and mesothelioma : how does it work ?
• Willems Luc ULiège
  • Fine tuned regulation of DNA damage tolerance by ubiquitination